Induced pluripotent stem (iPS) cells are a type of pluripotent stem cells resembling embryonic stem (ES) cells and can be derived from adult somatic cells by forced expression of certain genes. Both human ES and iPS cells are able to give rise to all the fully differentiated tissues and may provide an ideal source for the production of heart cells for cell-based therapies. Although human iPS cell-derived cardiomyocytes are functionally comparable to those derived from human ES cells in vitro, their functionality has not been compared in a physiologically relevant context. This proposal will test the hypothesis that human iPS cell- derived heart cells are the functional equivalent of their human ES cell-derived counterparts and thus provide an autologous cell source for cardiac repair and cardiovascular research. A mixture of cell types enriched for heart cells can be isolated from human ES and iPS cells in culture, but in order to create functional heart tissue and obtain reproducible results in cell-based therapies, it is critically important to isolate pure populations of cardiac cells that will engraft and promote cardiac repair. Ventricular cardiomyocytes (VCM) are the major cell type injured in patient's hearts, resulting in reduced cardiac function. While implanted VCM may be the optimal mature cell type to readily couple electrically with host VCM, our recent discovery of ISL1+ cardiovascular progenitor cells (ICPC) may represent a better source for cell-based therapies as these are highly proliferative cells that have the capacity to differentiate into cardiomyocytes, smooth muscle cells and endothelial cells, all of which are required for cardiac repair. By combining bacterial artificial chromosomal (BAC) recombineering technology with human ES cell engineering, the Qyang laboratory has established human ES and iPS cell lines that harbor enhanced green fluorescent protein (eGFP) and puromycin-resistance (Puro) dual reporters controlled by the endogenous myosin light chain 2V (MLC2V) promoter, which is VCM specific. Such a strategy has enabled the Qyang laboratory to isolate highly purified VCM based on both GFP expression and Puro-resistance. We will use this same technology to derive pure ICPC by establishing human ES and iPS cell lines that harbor GFP and Puro dual reporters controlled by the endogenous ISL1 promoter. As a proof of principle study to generate patient-specific VCM and ICPC for cell-based therapies, the Qyang laboratory proposes to isolate and characterize VCM and ICPC heart cells generated from human iPS cells using traditional 2D cultures and a recently established, physiologically relevant 3D "cardiac organoid chamber" system in vitro as well as cardiac repair models in vivo. For cardiac repair in vivo, we will employ a recently developed "cell sheet engineering" technology to establish engineered heart tissues. For all experiments, heart cells derived from NIH-approved human ES cells will be used as controls.

Public Health Relevance

This research will lead to the production of pure, well-characterized ISL1+ cardiovascular progenitor cells and ventricular cardiomyocytes as an abundant renewable cell source for cardiac repair. Development of engineered cardiac tissues using human ES and iPS cell cultures will provide exciting opportunities for high- throughput, patient-specific evaluation of cardiac medicines and cell-based therapies for heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Scientist Development Award - Research (K02)
Project #
5K02HL101990-04
Application #
8473266
Study Section
Special Emphasis Panel (ZHL1-CSR-U (F1))
Program Officer
Carlson, Drew E
Project Start
2010-07-15
Project End
2015-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
4
Fiscal Year
2013
Total Cost
$98,364
Indirect Cost
$7,286
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Suh, Carol Y; Wang, Zelun; Bártulos, Oscar et al. (2014) Advancements in Induced Pluripotent Stem Cell Technology for Cardiac Regenerative Medicine. J Cardiovasc Pharmacol Ther 19:330-339
Dunworth, William P; Cardona-Costa, Jose; Bozkulak, Esra Cagavi et al. (2014) Bone morphogenetic protein 2 signaling negatively modulates lymphatic development in vertebrate embryos. Circ Res 114:56-66
Alcon, Andre; Cagavi Bozkulak, Esra; Qyang, Yibing (2012) Regenerating functional heart tissue for myocardial repair. Cell Mol Life Sci 69:2635-56
Hibino, Narutoshi; Duncan, Daniel R; Nalbandian, Ani et al. (2012) Evaluation of the use of an induced puripotent stem cell sheet for the construction of tissue-engineered vascular grafts. J Thorac Cardiovasc Surg 143:696-703
Lee, Min Young; Sun, Baonan; Schliffke, Simon et al. (2012) Derivation of functional ventricular cardiomyocytes using endogenous promoter sequence from murine embryonic stem cells. Stem Cell Res 8:49-57
Amos, Peter J; Cagavi Bozkulak, Esra; Qyang, Yibing (2012) Methods of cell purification: a critical juncture for laboratory research and translational science. Cells Tissues Organs 195:26-40
Ren, Yongming; Lee, Min Young; Schliffke, Simon et al. (2011) Small molecule Wnt inhibitors enhance the efficiency of BMP-4-directed cardiac differentiation of human pluripotent stem cells. J Mol Cell Cardiol 51:280-7
Lee, Min Young; Cagavi Bozkulak, Esra; Schliffke, Simon et al. (2011) High density cultures of embryoid bodies enhanced cardiac differentiation of murine embryonic stem cells. Biochem Biophys Res Commun 416:51-7